1357103-03-7

Basic information

• Product Name: [D₇]-5-((2-((3-methoxy-4,5-dimethylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one
• Synonyms: [D₇]-5-((2-((3-methoxy-4,5-dimethylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one
• CAS NO: 1357103-03-7
• Molecular Weight: 398.374
• Mol File: 1357103-03-7.mol

Chemical Properties

• CAS DataBase Reference: [D₇]-5-((2-((3-methoxy-4,5-dimethylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: [D₇]-5-((2-((3-methoxy-4,5-dimethylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one(1357103-03-7)
• EPA Substance Registry System: [D₇]-5-((2-((3-methoxy-4,5-dimethylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one(1357103-03-7)

Safety Data

• Hazardous Substances Data: 1357103-03-7(Hazardous Substances Data)

Upstream product

• 156054-85-2 thymine-α,α,α,6-d4 
• 1643543-57-0 [D₄]-2,4-dichloro-5-methylpyrimidine 

Relevant articles and documents

Synthesis of the isotopically labeled JAK1/3 inhibitor [D7]-R545 and its oxidative metabolite [D7]-R935: Protecting group-directed regioselective bromination to access 3,4,5-substituted anilines

An extensive medicinal chemistry campaign and subsequent SAR studies led to the discovery of the highly potent and selective JAK1/3 inhibitor R545. To support advanced pre-clinical DMPK studies of R545, the isotopically labeled versions of the drug and its metabolite R935 were required. Herein, we describe the development of synthetic routes to deuterium-labeled [D7]-R545 and its oxidative metabolite [D7]-R935. Deuterium atoms were introduced at several sites in the target molecules by employing a convergent synthesis strategy. The desired regiochemistry at the right-hand side of [D7]-R935 was established via a newly discovered protecting group-directed bromination. The described synthetic approach gave rise to the desired deuterium-labeled target compounds and sufficient quantities were synthesized to enable pre-clinical DMPK studies.

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are